Better Options for Chronic Cancer Pain
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Ann Arbor and Indianapolis, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 294 people, planned
- Started
- 7 Oct 2025
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 6 groups
- Treatments tested
- Multimodal pain care
- Medication optimization
- Buprenorphine rotation
- Opioid tapering
- Record updated
- 11 May 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Veterans must have had a qualifying solid tumor (bladder, breast, colorectal, head and neck, liver, lung, pancreas, prostate, or urinary tract) without evidence of active disease for at least 6 months
- Participants must be 6 months away from their last receipt of cytotoxic, radiation, or surgical cancer treatments but can be on hormonal or biologic therapies needed to sustain remission or cancer control
- Participants must report pain >=4 (on 0-10 NRS) on their last 3 recordings in the electronic medical record. Veterans should be on Long Term Opioid Therapy (LTOT) defined as:; a qualifying opioid analgesic dispensed within the prior 30 days; plus 150 days' supply of a qualifying opioid (fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone) in the 180 days before the most recent dispensing date with no between-fill gaps >40 days
- There must be advance agreement from their existing opioid prescriber to resume opioid prescribing after study
Who cannot take part
- Veterans with total daily opioid doses >= 300 Morphine Milligram Equivalents (MME) will be excluded (higher doses require tapering prior to rotation to buprenorphine, which is something the investigators do not want to examine in this study)
- Veterans with referrals or visits to a substance abuse clinic within the prior 2 years will be excluded to avoid including individuals requiring addiction expertise that is not available one the multidisciplinary pain teams
- The investigators will also exclude Veterans with:; current or past use of buprenorphine; active alcohol use disorder or substance use; risk factors for opioid overdose (e.g. active suicidality or history of self-directed violence); daily use of benzodiazepines; receipt of opioids from non-VA providers in the prior 3 months; or aberrant urine drug screen at baseline (cannabis is not exclusionary)
- To ensure the relevance of our work to as many Veteran cancer survivors as possible, the investigators will not exclude subjects meeting DSM criteria for opioid use disorder if their only source of opioids is the VA
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- VA Ann Arbor Healthcare System, Ann Arbor, MIAnn Arbor, United StatesContact: Maria J Silveira, MD MA MPHTaking people
- Richard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis, United StatesContact: David Haggstrom, MDNot yet recruiting
About the trial
What the trial wants to find out
This proposal is relevant to the 240,000 cancer survivors who continue to use opioids long after they have successfully completed treatment for cancer at the VHA, placing them at risk of opioid addiction and overdose, and other opioid-related problems. Yet, there are no programs at the VHA to help them find alternatives to opioids, nor evidence to inform the choice of interventions. This study will meet these needs by examining four interventions that are effective at reducing opioid use in patients with chronic musculoskeletal pain but have yet to be tested in cancer survivors on long term opioid therapy. The proposed work is relevant to the VHA Pain Office's mission to provide Veterans better pain management while limiting the risks of long-term opioid therapy and it aligns with VHA Research and Development's priority to examine clinical interventions for tapering opioids. Successful completion this project will keep VHA at the forefront of the battle against the opioid epidemic with a strategy that may be adapted to address the same needs in non-Veterans.
The 6 groups in the trial
- Multimodal pain care 9 monthsTreatment being tested
Findings from the comprehensive pain assessment will be used to inform an individualized, multimodal plan crafted by the team physician with the subject's collaboration
Treatment: Multimodal pain care
- Medication optimizationTreatment being tested
Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan.
Treatment: Multimodal pain care and Buprenorphine rotation
- Multimodal pain care 6 months / Opioid tapering 3 monthsTreatment being tested
Findings from the comprehensive pain assessment will be used to inform an individualized, multimodal plan crafted by the team physician with the subject's collaboration. After 6 mo, subjects will attempt to taper opioids
Treatment: Multimodal pain care and Opioid tapering
- Medication optimization 9 monthsTreatment being tested
Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
Treatment: Medication optimization
- Medication optimization 6 months/ Buprenorphine rotation 3 monthsTreatment being tested
Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain. After 6mo, subjects will receive buprenorphine and attempt to taper opioids for following 3 mo.
Treatment: Medication optimization and Buprenorphine rotation
- Medication optimization 6 months/ Opioid tapering 3 monthsTreatment being tested
Findings from the comprehensive pain assessment will be used to inform a medication-focused pain plan. Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain. After 6mo, subjects will attempt to taper opioids for following 3 mo.
Treatment: Medication optimization and Opioid tapering
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Better Options for Chronic Cancer Pain: a SMART Study
- Fit questions
- Built from NCT06574009, who can take part
- Record updated
- 11 May 2026